Geron Corporation GERN R2K

Healthcare · Biotechnology · United States

https://www.geron.com

Geron Corporation, a commercial-stage biopharmaceutical company, focuses on the development of therapeutics products for oncology. The company's product pipeline includes RYTELO, a telomerase inhibitor for the treatment of adult patients with low- to intermediate-1 risk myelodysplastic syndromes with transfusion-dependent anemia; IMerge which is in Phase 3 clinical trial for the treatment of lower-risk myelodysplastic syndromes; IMpactMF that is in Phase 3 for the treatment of relapsed/refractory myelofibrosis; Impress which is in Phase 2 clinical trial to treat higher risk myelodysplastic syndromes and acute myeloid leukemia (AML); IMproveMF which is in Phase 1 clinical trial for the treatment of frontline myelofibrosis; and IMAGINE which is in phase 1/2 clinical trial for the treatment of relapsed/refractory AML. Geron Corporation was incorporated in 1990 and is headquartered in Foster City, California.

Market & Price

Market Cap

$801.90M

Current Price

$1.25

High / Low (52W)

$1.95 / $1.07

Beta

0.68

Valuation

Stock P/E

Industry PE

23.65

Forward P/E

19.23

PEG Ratio

Book Value

$0.36

Price to Book

3.50

P/S

4.09

EV/EBITDA

-17.67

Dividend Yield

Profitability & Returns

ROCE

-11.08%

ROE

-27.07%

ROA

-4.00%

Profit Margin

-34.32%

Op Margin

-0.46%

EPS (Latest Qtr)

$-0.01

EPS (TTM)

$-0.11

Balance Sheet & Liquidity

Debt/Equity

0.53

Quick Ratio

4.85

Current Ratio

6.78

Debt

$122.07M

Total Assets

$570.54M

Current Assets

$520.27M

Working Capital

$408.73M

Ownership

Promoter Holding

0.08%

Chg in Prom Hold

FII / Inst Holding

79.29%

Chg in FII Hold

-0.00%

Financial Snapshot

Enterprise Value

$611.57M

Total Revenue (TTM)

$196.12M

EBITDA

$-34.61M

Free Cash Flow

$-92.14M

Operating Cash Flow

$-125.96M

Shares Outstanding

641.52M

Gross Margin

60.97%

Payout Ratio

0.00%

Growth (CAGR)

Revenue 5Y

575.71%

Profit 5Y

13.72%

Revenue (YoY)

30.90%

Earnings (YoY)

PROS

Compounding revenue at 575.7% over 5 years.
Profit CAGR of 13.7% over 5 years.
In a confirmed uptrend (50-DMA above 200-DMA).

CONS

Trading 35.9% below its 52-week high.

* The pros and cons are auto-generated from financial metrics.

Price Chart

Robinhood TradingView StockAnalysis

Fundamental Growth

Period: Metric:

Figures from the latest reported periods. CAGR is computed across the displayed window (quarterly CAGR is annualised assuming 4 quarters per year).

Peer comparison

Peer companies in the same sector (Healthcare).

#	Name	CMP $	P/E	Mkt Cap	Div Yld %	ROCE %	ROE %	Rev CAGR 5Y %	Profit CAGR 5Y %
1	GERN Geron Corporation R2K	1.25	-	$801.90M	-	-11.08%	-27.07%	575.71%	13.72%
2	LLY Eli Lilly and Company SPX	1,105.00	39.21	$985.37B	0.63%	38.44%	107.46%	31.69%	48.96%
3	JNJ Johnson & Johnson SPX	225.33	26.11	$542.42B	2.38%	23.13%	26.42%	5.60%	14.32%
4	UNH UnitedHealth Group Incorporated SPX	380.31	28.66	$345.38B	2.32%	9.60%	12.18%	11.35%	-15.69%
5	MRK Merck & Co., Inc. SPX	118.72	33.44	$293.22B	2.86%	20.66%	18.94%	3.12%	7.93%
6	TMO Thermo Fisher Scientific Inc. SPX	492.51	27.11	$183.03B	0.38%	9.17%	13.52%	-0.27%	-1.19%
7	AMGN Amgen Inc. NDXSPX	336.79	23.42	$181.77B	2.99%	18.02%	101.32%	11.77%	5.58%
8	GILD Gilead Sciences, Inc. NDXSPX	134.43	18.29	$166.90B	2.44%	22.92%	43.36%	2.57%	22.83%
9	ISRG Intuitive Surgical, Inc. NDXSPXAI	424.64	51.53	$150.39B	-	15.96%	17.23%	17.39%	29.26%

Quarterly Results

Figures in USD.

Metric	Jun 2015	Sep 2015	Dec 2015	Mar 2016	Jun 2016	Sep 2016	Dec 2016	Mar 2017	Jun 2017	Sep 2017	Dec 2017	Mar 2018	Jun 2018	Sep 2018	Dec 2018	Mar 2019	Jun 2019	Sep 2019	Dec 2019	Mar 2020	Jun 2020	Sep 2020	Mar 2021	Jun 2021	Sep 2021	Mar 2022	Jun 2022	Sep 2022	Mar 2023	Jun 2023	Sep 2023	Mar 2024	Jun 2024	Sep 2024	Dec 2024	Mar 2025	Jun 2025	Sep 2025	Dec 2025	Mar 2026
Revenue	-	-	-	-	-	-	-	537.00K	174.00K	163.00K	191.00K	318.00K	208.00K	165.00K	375.00K	57.00K	101.00K	131.00K	171.00K	52.00K	43.00K	108.00K	137.00K	107.00K	109.00K	123.00K	73.00K	297.00K	21.00K	29.00K	164.00K	304.00K	882.00K	-	-	39.60M	49.04M	47.23M	48.02M	51.84M
Cost of Revenue	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	1.21M	1.19M	1.04M	1.31M	1.69M
Gross Profit	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	38.40M	47.85M	46.18M	46.71M	50.15M
Operating Expenses	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	55.10M	60.30M	60.07M	55.22M	50.38M
Operating Income	-9.48M	27.02M	-	-9.08M	-8.91M	-3.88M	-	-7.49M	-6.73M	-7.24M	-	-7.44M	-7.24M	-6.80M	-	-11.30M	-15.22M	-15.97M	-	-16.87M	-16.76M	-20.02M	-28.45M	-28.89M	-25.67M	-28.68M	-27.98M	-39.95M	-40.09M	-51.95M	-47.61M	-56.13M	-69.33M	-	-	-16.70M	-12.45M	-13.89M	-8.51M	-236.00K
EBITDA	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-11.33M	-7.55M	-9.47M	-21.29M	3.83M
Interest Expense	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	8.20M	8.52M	8.64M	7.30M	7.15M
Pretax Income	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-19.84M	-16.38M	-18.43M	-28.86M	-3.64M
Tax Provision	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Net Income	-9.36M	27.18M	-8.47M	-8.84M	-8.64M	-3.58M	-8.48M	-7.18M	-6.41M	-6.90M	-7.43M	-7.19M	-6.93M	-5.60M	-7.30M	-10.06M	-14.24M	-15.18M	-29.07M	-16.36M	-15.82M	-19.65M	-27.82M	-29.57M	-26.70M	-30.10M	-28.12M	-41.05M	-38.12M	-49.23M	-44.80M	-55.39M	-67.38M	-	-	-19.84M	-16.38M	-18.43M	-28.86M	-3.64M
Diluted EPS	-	0.17	-	-	-	-0.02	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-0.09	-0.08	-0.09	-0.07	-0.10	-0.07	-0.09	-0.08	-0.09	-0.10	-	-	-0.03	-0.02	-0.03	-0.05	-0.01

Profit & Loss (Annual)

Figures in USD.

Metric	Dec 2009	Dec 2010	Dec 2011	Dec 2012	Dec 2013	Dec 2014	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024	Dec 2025
Revenue	-	-	-	-	-	-	-	6.16M	1.06M	1.07M	460.00K	253.00K	-	596.00K	237.00K	76.99M	183.88M
Cost of Revenue	-	-	-	-	-	-	-	-	-	-	-	-	-	0	0	1.26M	4.75M
Gross Profit	-	-	-	-	-	-	-	-	-	-	-	-	-	596.00K	237.00K	75.74M	179.14M
Operating Expenses	-	-	-	-	-	-	-	-	-	-	-	-	-	139.15M	194.18M	249.47M	230.69M
Operating Income	-70.23M	-111.17M	-96.12M	-71.76M	-38.96M	-36.31M	-559.00K	-30.65M	-29.25M	-31.07M	-72.50M	-76.91M	-	-138.55M	-193.94M	-173.73M	-51.55M
EBITDA	-	-	-	-	-	-	-	-	-	-	-	-	-	-134.15M	-174.78M	-154.85M	-49.64M
Interest Expense	-	-	-	-	-	-	-	-	-	-	-	-	-	6.88M	8.31M	18.50M	32.66M
Pretax Income	-	-	-	-	-	-	-	-	-	-	-	-	-	-141.90M	-184.13M	-174.57M	-83.50M
Tax Provision	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Net Income	-70.18M	-111.38M	-96.85M	-68.88M	-38.38M	-35.67M	46.00K	-29.54M	-27.92M	-27.02M	-68.55M	-75.62M	-	-141.90M	-184.13M	-174.57M	-83.50M
Diluted EPS	-	-	-	-	-0.30	-0.23	0.00	-0.19	-0.18	-	-	-0.28	-	-0.37	-0.32	-0.27	-0.13

Compounded Sales Growth

5 Years:	575.71%
1 Year:	30.90%

Compounded Profit Growth

5 Years:	13.72%
1 Year:	-

Stock Price Performance

1 Year:	-17.76%
6 Months:	+7.76%
3 Months:	-25.60%
1 Month:	-17.22%

Balance Sheet (Annual)

Figures in USD.

Metric	Dec 2008	Dec 2009	Dec 2010	Dec 2011	Dec 2012	Dec 2013	Dec 2014	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024	Dec 2025
Total Assets	-	-	233.58M	160.05M	99.80M	67.34M	172.51M	148.76M	130.25M	110.31M	185.28M	165.52M	270.73M	-	190.57M	394.08M	593.78M	570.54M
Current Assets	-	-	-	-	-	-	-	-	-	-	-	-	-	-	180.25M	341.35M	490.99M	520.27M
Cash & Equivalents	109.35M	34.60M	45.97M	16.11M	22.06M	12.99M	42.80M	21.25M	12.81M	16.34M	10.57M	13.64M	9.93M	-	56.84M	70.02M	79.02M	77.56M
Inventory	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	38.71M	116.64M
Receivables	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	35.95M	36.99M
Total Liabilities	-	-	-	-	-	-	-	-	-	-	-	30.36M	59.78M	-	110.58M	146.13M	313.46M	344.67M
Current Liabilities	-	-	40.85M	13.44M	14.15M	7.59M	41.80M	6.63M	7.87M	6.52M	7.55M	28.16M	30.94M	-	76.69M	108.07M	88.30M	111.54M
Long Term Debt	-	-	-	-	-	-	-	-	-	-	-	-	24.04M	-	30.21M	35.05M	118.48M	119.55M
Total Debt	-	-	-	-	-	-	-	-	-	-	-	-	-	-	55.75M	85.90M	121.72M	121.99M
Total Equity	168.46M	172.58M	192.74M	146.60M	85.65M	59.76M	130.71M	142.13M	122.38M	103.80M	177.73M	135.16M	210.95M	-	80.00M	247.95M	280.32M	225.87M
Shares Outstanding	-	-	-	-	-	-	-	-	-	-	-	-	-	-	390.26M	544.91M	606.39M	639.86M

Cash Flows (Annual)

Figures in USD.

Metric	Dec 2009	Dec 2010	Dec 2011	Dec 2012	Dec 2013	Dec 2014	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024	Dec 2025
Operating Cash Flow	-43.37M	-44.29M	-62.39M	-	-	-	-24.20M	-18.37M	-20.56M	-21.01M	-43.83M	-66.65M	-	-127.38M	-167.74M	-218.62M	-111.04M
Investing Cash Flow	-83.00M	-48.45M	32.14M	-	-	-	73.00K	8.76M	22.97M	-77.72M	27.40M	-105.32M	-	62.07M	-180.32M	-106.00M	107.25M
Financing Cash Flow	51.63M	104.11M	386.00K	-	-	-	2.58M	1.17M	1.11M	92.97M	19.50M	168.35M	-	87.26M	362.02M	334.37M	2.27M
Capital Expenditure	-1.44M	-836.00K	-612.00K	-862.00K	-3.00K	-131.00K	-90.00K	-57.00K	-	-16.00K	-413.00K	-401.00K	-	-431.00K	-830.00K	-680.00K	-49.00K
Free Cash Flow	-44.81M	-45.13M	-63.00M	-	-	-	-24.29M	-18.43M	-	-21.02M	-44.24M	-67.05M	-	-127.81M	-168.57M	-219.30M	-111.09M
Net Change in Cash	-	-	-	-	-	-	-	-	-	-	-	-	-	21.95M	13.96M	9.75M	-1.52M

Ratios (Annual)

Figures in %.

Metric	Dec 2009	Dec 2010	Dec 2011	Dec 2012	Dec 2013	Dec 2014	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024	Dec 2025
Gross Margin %	-	-	-	-	-	-	-	-	-	-	-	-	-	100.0%	100.0%	98.4%	97.4%
Operating Margin %	-	-	-	-	-	-	-	-497.3%	-2,746.9%	-2,914.9%	-15,762.0%	-30,400.4%	-	-23,246.6%	-81,832.9%	-225.6%	-28.0%
Net Margin %	-	-	-	-	-	-	-	-479.3%	-2,621.2%	-2,534.4%	-14,901.7%	-29,888.1%	-	-23,808.9%	-77,690.7%	-226.7%	-45.4%
ROE %	-40.7%	-57.8%	-66.1%	-80.4%	-64.2%	-27.3%	0.0%	-24.1%	-26.9%	-15.2%	-50.7%	-35.8%	-	-177.4%	-74.3%	-62.3%	-37.0%
ROCE %	-	-57.7%	-65.6%	-83.8%	-65.2%	-27.8%	-0.4%	-25.0%	-28.2%	-17.5%	-52.8%	-32.1%	-	-121.7%	-67.8%	-34.4%	-11.2%

Shareholding Pattern

Insiders

0.08%

Institutions

79.29%

Public Float

79.36%

Top Institutional Holders

#	Holder	% Held	Shares	Value
1	RA Capital Management, L.P.	9.94%	63.77M	$79.71M
2	Blackrock Inc.	7.38%	47.32M	$59.15M
3	Soleus Capital Management, L.P.	6.47%	41.51M	$51.89M
4	Deep Track Capital, Lp	4.94%	31.72M	$39.65M
5	State Street Corporation	4.75%	30.50M	$38.12M
6	Vanguard Capital Management LLC	4.16%	26.67M	$33.34M
7	Citadel Advisors Llc	3.36%	21.58M	$26.97M
8	Point72 Asset Management, L.P.	3.19%	20.46M	$25.57M
9	ClearBridge Investments, LLC	3.06%	19.62M	$24.53M
10	Eversept Partners, LP	2.94%	18.83M	$23.54M

Analyst View

Loading analyst coverage…

Latest News

Recent headlines for GERN

No recent headlines available.

GERN · Healthcare